Kangmei Pharmaceutical Co., Ltd. (SHA: 600518)

Kangmei Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Jun 30, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	794.97	1,057	1,507	2,419	552.34	501.2
Short-Term Investments	-	-	-	-	-	5.88
Trading Asset Securities	0.07	0.08	0.12	0.52	-	-
Cash & Short-Term Investments	795.04	1,057	1,508	2,419	552.34	507.08
Cash Growth	-37.80%	-29.91%	-37.68%	337.98%	8.93%	-72.37%
Accounts Receivable	2,261	2,095	2,046	1,460	2,487	3,855
Other Receivables	904.9	874.44	888.79	1,052	9,559	10,618
Receivables	3,166	2,969	2,935	2,512	12,046	14,473
Inventory	2,887	2,644	2,751	3,195	5,709	31,408
Prepaid Expenses	0.04	0.69	0	-	0.01	-
Other Current Assets	145.83	139.28	190.85	158.8	234.39	625.09
Total Current Assets	6,994	6,810	7,384	8,285	18,541	47,013
Property, Plant & Equipment	3,738	3,875	4,180	4,642	9,603	11,409
Long-Term Investments	1.12	1.15	1.39	1	1	1.04
Goodwill	106.35	106.35	106.35	106.35	36.91	81.2
Other Intangible Assets	469.98	491.02	529.79	579.73	1,309	2,022
Long-Term Deferred Tax Assets	100.4	101.48	96.97	60.69	240.96	256.7
Long-Term Deferred Charges	61.48	66.47	86.71	110.22	111.57	244.23
Other Long-Term Assets	2,786	2,829	2,783	2,269	3,483	3,558
Total Assets	14,257	14,280	15,169	16,054	33,326	64,586
Accounts Payable	2,523	2,256	2,563	2,015	3,762	3,774
Accrued Expenses	521.26	873.71	1,328	1,134	2,066	934.9
Short-Term Debt	23.41	26.14	25.62	15.17	2,315	12,811
Current Portion of Long-Term Debt	-	-	-	-	-	5,113
Current Portion of Leases	36.28	40.71	39.12	36.89	-	-
Current Income Taxes Payable	26.09	24.74	26.2	140.5	112.15	125.79
Current Unearned Revenue	151.91	159.89	158.12	193.85	455.19	-
Other Current Liabilities	1,420	1,298	1,301	1,411	14,576	5,064
Total Current Liabilities	4,702	4,680	5,442	4,947	23,286	27,823
Long-Term Debt	-	-	-	-	19,415	15,010
Long-Term Leases	176.46	188.16	199.13	153.22	-	-
Long-Term Unearned Revenue	603.42	618.68	653.98	692.97	1,035	1,103
Long-Term Deferred Tax Liabilities	46.43	51.68	55.53	-	0.05	0.08
Other Long-Term Liabilities	1,629	1,661	1,835	293.02	-	-
Total Liabilities	7,157	7,200	8,185	6,086	43,736	43,935
Common Stock	13,864	13,864	13,864	13,864	4,974	4,974
Additional Paid-In Capital	18,783	18,783	18,783	18,783	11,576	11,553
Retained Earnings	-24,360	-24,375	-24,478	-21,790	-29,706	1,368
Treasury Stock	-1,224	-1,225	-1,222	-932.82	-343.6	-343.6
Comprensive Income & Other	1.12	1.18	1.43	3.1	-3.74	-3.51
Total Common Equity	7,064	7,048	6,948	9,927	-13,504	17,548
Minority Interest	35.75	32.89	35.43	41.92	126.47	135.72
Shareholders' Equity	7,100	7,080	6,984	9,968	-10,410	20,651
Total Liabilities & Equity	14,257	14,280	15,169	16,054	33,326	64,586
Total Debt	236.15	255.01	263.87	205.29	21,730	32,934
Net Cash (Debt)	558.89	801.68	1,244	2,214	-21,178	-32,427
Net Cash Growth	-45.57%	-35.54%	-43.82%	-	-	-
Net Cash Per Share	0.05	0.08	0.09	0.16	-1.53	-6.57
Filing Date Shares Outstanding	13,864	13,864	13,864	13,864	4,974	4,974
Total Common Shares Outstanding	13,864	13,864	13,864	13,864	4,974	4,974
Working Capital	2,292	2,130	1,942	3,338	-4,745	19,190
Book Value Per Share	0.51	0.51	0.50	0.72	-2.71	3.53
Tangible Book Value	6,488	6,450	6,312	9,240	-14,849	15,444
Tangible Book Value Per Share	0.47	0.47	0.46	0.67	-2.99	3.11
Buildings	5,229	5,229	5,401	5,665	8,359	7,039
Machinery	1,167	820.08	826.65	1,206	2,799	3,530
Construction In Progress	172.64	210.56	215.5	263.65	1,630	3,714

Source: S&P Capital IQ. Standard template. Financial Sources.